Heart Failure Research

Heart failure, also known as congestive heart failure or CHF, is an inability of the heart to pump sufficient blood around the body.Heart failure typically occurs secondary to an existing pathology that alters cardiac function. Examples of syndromes that can precede heart failure include myocardial infarction, arrhythmia or infection. These can also cause dilated cardiomyopathy, a condition which accounts for approximately one third of all cases of heart failure. The pathogenesis of heart failure is cyclical and progressive; endogenous mechanisms, which are activated during heart failure in an attempt to counteract the symptoms, actually worsen cardiac function. Cardiac dysfunction, either systolic or diastolic, triggers a decrease in stroke volume and a resultant increase in cardiac output. In healthy individuals the body responds to decreases in cardiac output by initiating the renin-angiotensin-aldosterone system (RAAS) to promote fluid retention, and also by activating the sympathetic nervous system to cause peripheral vasoconstriction. Under normal circumstances this counteracts the imbalance in stroke volume, restoring cardiac output to normal levels. In patients with heart failure the increase in blood volume, together with the heightened peripheral resistance and elevated levels of circulating catecholamines, causes an increased load on the already weakened ventricles with each contraction, and the stroke volume does not return to normal levels. Repeated cycles of this process further weaken the ventricle walls, prompting ventricular hypertrophy and a decreased force of contraction.

Heart Failure Research Products Targets

Products for Heart Failure Research - Page 12

  1. Cat.No. Product Name Information/Activity
  2. BCC2143 Olmesartan medoxomil Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM. Olmesartan medoxomil chemical structure
  3. BCC3863 Telmisattan Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM. Telmisattan chemical structure
  4. BCC5017 Valsartan Valsartan (CGP-48933) is an angiotensin II receptor antagonist for the treatment of high blood pressure and heart failure. Valsartan chemical structure
  5. BCC5734 ZD 7155 hydrochloride ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist. ZD 7155 hydrochloride chemical structure
  6. BCC6051 Novokinin 358738-77-9 Novokinin chemical structure
  7. BCC5010 PD123319 PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM. PD123319 chemical structure
  8. BCC5921 CGP 42112 CGP-42112(CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist. CGP 42112 chemical structure
  9. BCC6689 L-NIO dihydrochloride L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively. L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats. L-NIO dihydrochloride chemical structure
  10. BCC6795 Aminoguanidine hydrochloride Aminoguanidine hydrochloride is a diamine oxidase and NO synthase inhibitor, reduces levels of advanced glycation end products (AGEs) through interacting with 3-deoxyglucosone, is an investigational drug for the treatment of diabetic nephropathy. Aminoguanidine hydrochloride chemical structure
  11. BCC6823 AMT hydrochloride 21463-31-0 AMT hydrochloride chemical structure

Items 111 to 120 of 148 total